After finishing at $12.77 in the prior trading day, Stoke Therapeutics Inc (NASDAQ: STOK) closed at $12.21, down -4.39%. On the day, 2370827 shares were traded. STOK stock price reached its highest trading level at $12.82 during the session, while it also had its lowest trading level at $12.00.
Ratios:
Our goal is to gain a better understanding of STOK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.99 and its Current Ratio is at 6.99. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’24 when Nash Huw M. sold 61,329 shares for $13.23 per share. The transaction valued at 811,212 led to the insider holds 0 shares of the business.
Ticho Barry sold 9,426 shares of STOK for $124,684 on Apr 01 ’24. The CHIEF MEDICAL OFFICER now owns 2,485 shares after completing the transaction at $13.23 per share. On Mar 28 ’24, another insider, Allan Jonathan, who serves as the GENERAL COUNSEL & CORP SEC of the company, sold 5,126 shares for $13.20 each. As a result, the insider received 67,668 and left with 2,598 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 72.12 while its Price-to-Book (P/B) ratio in mrq is 3.51.
Stock Price History:
Over the past 52 weeks, STOK has reached a high of $16.40, while it has fallen to a 52-week low of $3.35.
Shares Statistics:
A total of 45.92M shares are outstanding, with a floating share count of 32.97M. Insiders hold about 36.43% of the company’s shares, while institutions hold 56.38% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 9 different market analysts. On average, analysts expect EPS of -$0.61 for the current quarter, with a high estimate of -$0.54 and a low estimate of -$0.7, while EPS last year was -$0.53. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.43 and low estimates of -$0.63.
Analysts are recommending an EPS of between -$2 and -$2.62 for the fiscal current year, implying an average EPS of -$2.31. EPS for the following year is -$2.52, with 9 analysts recommending between -$1.62 and -$3.45.
Revenue Estimates
7 analysts predict $3.21M in revenue for the current quarter. It ranges from a high estimate of $4M to a low estimate of $2M. As of the current estimate, Stoke Therapeutics Inc’s year-ago sales were $5.15M, an estimated decrease of -37.70% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $3.36M, a decrease of -235.40% less than the figure of -$37.70% in the same quarter last year. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $2M.
A total of 9 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $20M, while the lowest revenue estimate was –$, resulting in an average revenue estimate of $12.33M. In the same quarter a year ago, actual revenue was $8.78M, up 40.40% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $15.73M in the next fiscal year. The high estimate is $60M and the low estimate is –$. The average revenue growth estimate for next year is up 27.60% from the average revenue estimate for this year.
